

Min Hee Hong

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8851689/min-hee-hong-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78

papers

1,280

citations

20

h-index

34

g-index

89

ext. papers

1,860

ext. citations

5.3

avg, IF

4.58

L-index

#	Paper	IF	Citations
78	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. <i>Scientific Reports</i> , 2016 , 6, 36956	4.9	154
77	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019 , 30, 1104-1113	10.3	120
76	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of Exon 20 Insertion-Driven NSCLC. <i>Cancer Discovery</i> , 2020 , 10, 1194-1209	24.4	68
75	Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1373-1382	8.9	57
74	Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. <i>Cancer Research and Treatment</i> , 2009 , 41, 67-72	5.2	57
73	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. <i>Immune Network</i> , 2020 , 20, e10	6.1	51
72	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. <i>Lancet Oncology</i> , 2019 , 20, 1681-1690	21.7	47
71	Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. <i>Oncology</i> , 2011 , 80, 395-405	3.6	45
70	Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 1065-1073	4	41
69	Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1613-1623	4.9	40
68	Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. <i>Annals of Oncology</i> , 2017 , 28, 1250-1259	10.3	37
67	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 2575-2587	12.9	33
66	Clinical value of ezrin expression in primary osteosarcoma. <i>Cancer Research and Treatment</i> , 2009 , 41, 138-44	5.2	33
65	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3287-3295	12.9	26
64	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018 , 78, 3350-3362	10.1	23
63	Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. <i>Experimental and Molecular Medicine</i> , 2020 , 52, 1550-1563	12.8	22
62	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. <i>Clinical Cancer Research</i> , 2021 , 27, 2168-2178	12.9	22

61	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. <i>EMBO Molecular Medicine</i> , 2019 , 11, e10581	12	21
60	Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. <i>Cancer Research and Treatment</i> , 2009 , 41, 196-204	5.2	21
59	ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2018 , 37, 377-388	9.2	20
58	Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 797-805	3.5	20
57	Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. <i>Oncotarget</i> , 2017 , 8, 65111-65122	3.3	17
56	A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. <i>Lung Cancer</i> , 2019 , 134, 46-51	5.9	16
55	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. <i>Scientific Reports</i> , 2020 , 10, 9050	4.9	16
54	Prognosis of pN3 stage gastric cancer. <i>Cancer Research and Treatment</i> , 2009 , 41, 73-9	5.2	16
53	Real-World Analysis of the Efficacy of Rebiopsy and Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2019 , 60, 525-534	3	15
52	Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. <i>Lung Cancer</i> , 2018 , 121, 12-17	5.9	15
51	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. <i>Lung Cancer</i> , 2018 , 124, 168-178	5.9	15
50	Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA hybridization. <i>Oncotarget</i> , 2017 , 8, 87234-87243	3.3	14
49	Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. <i>Lung Cancer</i> , 2019 , 131, 139-146	5.9	13
48	Dynamic changes in PD-L1 expression and CD8 T cell infiltration in non-small cell lung cancer following chemoradiation therapy. <i>Lung Cancer</i> , 2019 , 136, 30-36	5.9	13
47	Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. <i>Head and Neck</i> , 2018 , 40, 55-62	4.2	11
46	A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4027-4027	2.2	11
45	Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. <i>PLoS ONE</i> , 2019 , 14, e0224379	3.7	9
44	High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma. <i>Scientific Reports</i> , 2019 , 9, 20197	4.9	9

43	Dynamic changes in circulating PD-1CD8 T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021 , 143, 113-126	7.5	9
42	Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response. <i>British Journal of Cancer</i> , 2020 , 122, 1649-1660	8.7	8
41	Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. <i>British Journal of Cancer</i> , 2020 , 123, 1720-1729	8.7	8
40	P3.02b-119 YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1265-S1266	8.9	7
39	Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in -positive non-small-cell lung cancer 2020 , 8,		7
38	Establishment and characterization of patient-derived xenografts as preclinical models for head and neck cancer. <i>BMC Cancer</i> , 2020 , 20, 316	4.8	7
37	The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2020 , 12, 6426-6434	2.6	6
36	Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 799-808	3.5	6
35	Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma. <i>Scientific Reports</i> , 2019 , 9, 19909	4.9	6
34	Povidone-iodine for the management of oral mucositis during cancer therapy. <i>Oncology Reviews</i> , 2017 , 11, 341	4.3	5
33	Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 405-414	3.5	5
32	Incidence, in-hospital mortality, and readmission among patients with alcoholic hepatitis in Korea: A nationwide study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 747-754	4	5
31	Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case Report. <i>Ocular Immunology and Inflammation</i> , 2020 , 28, 864-867	2.8	5
30	Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021 , 153, 179-189	7.5	5
29	Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy.. <i>Radiotherapy and Oncology</i> , 2022 ,	5.3	4
28	A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	4
27	Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Cancer</i> , 2020 , 126, 4521-4531	6.4	3
26	Distinct Characteristics and Clinical Outcomes to Predict the Emergence of Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021 , 13,	6.6	3

25	The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.. <i>Frontiers in Oncology</i> , 2022 , 12, 811247	5.3	3
24	YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9033-9033	2.2	2
23	Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma. <i>Scientific Reports</i> , 2021 , 11, 8551	4.9	2
22	Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy. <i>Cancers</i> , 2021 , 13,	6.6	2
21	Abstract 1106: BRAF and EGFR fusion as a novel mechanism of resistance mechanism to Lazertinib, 3rd- generation EGFR-TKI, in EGFR-mutant NSCLC 2021 ,		2
20	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021 , 10, 7012-7020	4.8	2
19	Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents. <i>Kidney Research and Clinical Practice</i> , 2021 , 40, 344-354	3.6	2
18	SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models.. <i>Clinical and Translational Immunology</i> , 2022 , 11, e1364	6.8	2
17	Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate. <i>PLoS ONE</i> , 2019 , 14, e0214291	3.7	1
16	Mesoporous Thin Films: Thermoelectric Application. <i>Applied Mechanics and Materials</i> , 2012 , 260-261, 34-39	0.3	1
15	Predicting treatment outcomes using F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359211068732	5.4	1
14	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor.. <i>Yonsei Medical Journal</i> , 2022 , 63, 42-55	3	1
13	Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients. <i>Scientific Reports</i> , 2021 , 11, 7435	4.9	1
12	Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study. <i>Cancers</i> , 2021 , 13,	6.6	1
11	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2459-2469	4.9	1
10	Disproportional enrichment of FoxP3 CD4 regulatory T cells shapes a suppressive tumour microenvironment in head and neck squamous cell carcinoma.. <i>Clinical and Translational Medicine</i> , 2022 , 12, e753	5.7	1
9	Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021 , 27, 1076029620979575	3.3	0
8	Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2741-2750	4.9	0

7	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	○
6	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221079125	5.4	○
5	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.. <i>Frontiers in Oncology</i> , 2022 , 12, 821391	5.3	○
4	Synthesize of Mesoporous ZnO Thin Films and Gas Sensing Property. <i>Advanced Materials Research</i> , 2014 , 960-961, 157-160	0.5	
3	MAPK-signaling inhibition as a genome-based precision medicine in refractory osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22164-e22164	2.2	
2	Everolimus-associated pneumonitis in Asian metastatic renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15596-e15596	2.2	
1	Phase II study of afatinib in recurrent and/or metastatic esophageal squamous cell carcinoma (R/M ESCC) (KCSG HN14-18).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4051-4051	2.2	